Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  brain tumor
Stage/Subtype:  brain tumor
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-15 of 15 for your search:
Start Over
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Vaccine Therapy with Bevacizumab or Bevacizumab Alone in Treating Patients with Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A071101, NCI-2013-00444, NCT01814813
ERC1671/GM-CSF/Cyclophosphamide in Treating Patients with Relapsed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ERC1671-H02, NCI-2014-00737, 11922, ERC1671, UCI 13-14, NCT01903330
Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 months to less than 22 years
Trial IDs: LGG Vaccine Trial, NCI-2016-00644, NCT02358187
Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00054740, NCI-2015-00856, NCT02366728
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259614, NCI-2015-00694, NCT02455557
Vaccine Therapy and Temozolomide in Treating Patients with Recurrent Glioma Expressing IDH1
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00054746, NCI-2015-02213, NCT02193347
Vaccine Therapy and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-362, NCI-2014-02645, NCT02287428
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI-DSP7888-101, NCI-2015-01357, NCT02498665
Nivolumab with or without Vaccine Therapy in Treating Patients with Recurrent Brain Tumors Undergoing Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: Pro00065241, NCI-2016-00059, NCT02529072
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 19 months to 20 years
Trial IDs: Glioma Vaccine, NCI-2016-00993, NCT01130077
Vaccine Therapy and Imiquimod in Treating Patients With High Risk or Recurrent Grade II Gliomas
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 11-136, NCI-2013-00078, NCT01678352
HLA-A2 Restricted Peptide Vaccine and Imiquimod in Treating Children with Recurrent Ependymoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: Ependymoma Vaccine, NCI-2016-01096, NCT01795313
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 70
Trial IDs: 0202EA, NCI-2014-02473, NCT02146066
Neoantigen-based Glioblastoma Vaccine and Poly-ICLC Vaccine in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201510022, NCI-2015-01776, NCT02510950
Start Over